Expertise in
17
conditions

Dr. Kevin F. Ginn

Hematology | Oncology
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
17
conditions
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 

Overview

Kevin Ginn is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri.

Dr. Ginn is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Glioma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 30 clinical trials. Dr. Ginn is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Children's Mercy Kansas City
2401 Gillham Rd, Kansas City, MO 64108
Other Locations
Office
5808 W 110th St, Leawood, KS 66211

Additional Areas of Focus

Dr. Ginn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Enrollment Status: Suspended
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure
Study Drug: FACT Complex-Targeting Curaxin CBL0137
Study Phase: Phase 1/Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
View 9 Less Clinical Trials

22 Total Publications

Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Journal: Acta neuropathologica
Published: September 03, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Referral may be required

Children's Mercy Kansas City

2401 Gillham Rd, 
Kansas City, MO 
 (0.1 miles away)
816-234-3265
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Gamis is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri. Dr. Gamis is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Leukemia, Acute Megakaryoblastic Leukemia, and Bone Marrow Transplant. Dr. Gamis is currently accepting new patients.

Expertise in
132
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Expertise in
132
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Referral may be required

Ascentist Physicians Group

4901 College Blvd, 
Leawood, KS 
 (11.4 miles away)
913-529-1801
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jaswinder Singh is a Hematologist and an Oncologist practicing medicine in Leawood, Kansas. Dr. Singh is highly rated in 132 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Singh is currently accepting new patients.

Expertise in
51
conditions
Expertise in
51
conditions
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (5.1 miles away)
913-588-1227
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist practicing medicine in Fairway, Kansas. Dr. Yacoub is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is board certified in American Board Of Internal Medicine, Hematology - 2012 and American Board Of Internal Medicine, Medical Oncology - 2011. Dr. Yacoub is currently accepting new patients.

Frequently Asked Questions about Dr. Kevin F. Ginn

How do I make an appointment with Dr. Kevin F. Ginn?

You can book an appointment with Dr. Kevin F. Ginn by calling their office at 816-234-3265. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin F. Ginn a top-rated expert for Medulloblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin F. Ginn is classified as an Distinguished expert for Medulloblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin F. Ginn specialize in?

While Dr. Kevin F. Ginn is a Hematology, they have specific expertise in Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Gliomatosis Cerebri. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kevin F. Ginn participate in research or clinical trials?

Yes. Dr. Kevin F. Ginn has published 22 articles and abstracts on conditions like Medulloblastoma. You can view a list of Dr. Kevin F. Ginn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin F. Ginn accept my insurance?

Dr. Kevin F. Ginn accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 816-234-3265 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ginn's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile